Results From German CML Study IV on 84 Patients who Received a Matched Allogeneic Transplant Because of Either a High-Disease Risk Score at Diagnosis, Imatinib Failure, or Progressive Disease. Probability of overall survival after allogeneic transplant is shown in the top figure. The box on the bottom shows a matched pair analysis comparing chronic-phase patients receiving transplantation compared to patients receiving imatinib therapy.This figure was originally published in Blood.